Durata Therapeutics Inc., an affiliate of Allergan plc
Quick facts
Phase 3 pipeline
- IV Dalbavancin · Infectious Disease
Dalbavancin is a lipoglycopeptide antibiotic that inhibits bacterial cell wall synthesis by binding to D-Ala-D-Ala peptidoglycan precursors. - Vancomycin / Linezolid · Infectious Disease
Vancomycin inhibits cell wall synthesis in Gram-positive bacteria, while Linezolid inhibits protein synthesis by binding to the 50S ribosomal subunit.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Durata Therapeutics Inc., an affiliate of Allergan plc portfolio CI brief
- Durata Therapeutics Inc., an affiliate of Allergan plc pipeline updates RSS
Frequently asked questions about Durata Therapeutics Inc., an affiliate of Allergan plc
What is Durata Therapeutics Inc., an affiliate of Allergan plc's pipeline?
Durata Therapeutics Inc., an affiliate of Allergan plc has 2 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include IV Dalbavancin, Vancomycin / Linezolid.
Related
- Sector hub: All tracked pharma companies